Viaderma Inc (OTCMKTS:VDRM) Innovative Co With a Cannabis Twist

Viaderma Inc (OTCMKTS:VDRM) Innovative Co With a Cannabis Twist

SHARE

No one likes to talk about MSD (Male Sexual Dysfunction) drugs so it is surprising when you see a stock like Viaderma Inc (OTCMKTS:VDRM) take off. A little digging showed that this was a cannabis related move as the underpinnings are consistent with our theme of replacing pharma with CBD’s. But this should not surprise those who follow the Erectile Dysfunction (ED) market which is dominated by Cialis and Viagra.

But this stock is based on the sales of the topical market for ED which are reportedly up from about $684 million dollars in 2010. The topical market is expected to increase in value by around 10% in 2017 for US markets alone..

Viaderma Inc (OTCMKTS:VDRM) is a specialty pharmaceutical company devoted to bringing new products to market, recently announced that the Company has filed with the (FDA) Food and Drug Administration for a new over the counter or OTC version of its “Premature Ejaculation Drug”. The new “OTC Drug” should have FDA registration approval in approximately 8 weeks and the Company’s name of the new drug will portray prolonged endurance. The Company says it’s recent testing of the drug has proved to be successful in retarding the onset of ejaculation during sexual intercourse.

The market for male sexual dysfunction is dominated by Viagra and Cialis both are taken orally for Erectile Dysfunction (ED). The Company’s alternative is a topical solution that does not have to be ingested and processed through the digestive system. The Company believes there is a vast market for this type of non-orally ingested new product and should generate significant Company revenues starting in 2017.

Find out when Viaderma Inc stock reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.

This is another product in the “Go to Market Strategies” pipeline. The Company already has located a suitable distributor and is attempting to assure a solid strategy behind the launch once the FDA submission is approved. The Company is continuing the completion of the labeling, quality control, marketing, and distribution now for several products. The Company continues its plan for an aggressive growth for 2017 and the years ahead.

Premature ejaculation (PE) is the most common male sexual disorder, and it may have a profound negative impact on a man and his partner’s lives. Premature ejaculation sprays became available in the UK in last year in November, but men wishing to use it would have to visit their Doctor, who would then order the spray from a pharmaceutical company.

In the US, topical sprays that treat PE are available OTC. In reported testing these types of products work on 9 out of 10 men and can have them last twice as long during sexual intercourse. Research reports have found the premature ejaculation treatment segment of the sexual dysfunction market has been estimated to be $1.3 Billion dollars for 2017. Also, reported, the market for these types of products could become larger than the tablet or oral (ED) market.

ViaDerma, Inc. (OTCMKTS:VDRM) is a publicly traded specialty pharmaceutical company committed to bringing new products to market and licensing its innovative technology to current leaders in the pharmaceutical industry in a wide variety of therapeutic areas. ViaDerma’s lead product, Viabecline, uses an innovative transdermal delivery method that allows for application of active ingredients in a topical form. This patent-pending dual carrier transdermal technology may be applied in products within the medical and cosmetic markets. Also, a patent application using the combination of CBD’s and THC with the delivery system was filed in 2014. The use of CBD’s is for the reduction of inflammation and for the treatment of several diseases, such as, nicotine addiction, fibromyalgia, Cohn’s disease, schizophrenia, migraine headaches, pain management for cancer and Multiple Sclerosis.

VDRM is an innovative story with a Cannabis twist that replaces synthetics with a natural drug, which has been a positive theme in all small company trades occurring in 2017. It’s worth watching how this plays out in this niche market. Shares have been much higher than they are now, but a recent 25% bounce may show the company is getting some traction. We like these natural replacement story’s where a synthetic drug is being replaced by a CBD, and investors like investing in the stocks as they emerge. For continuing coverage on shares of Viaderma Inc, as well as our other hot stock picks, sign up for our free newsletter today and get our next hot stock pick!

Sign Up for our 100% FREE Oracle Dispatch Newsletter

Join our mailing list to receive the latest news and updates from our team.

Invalid email address

Sign Up for our 100% FREE Oracle Dispatch Newsletter

1 COMMENT

  1. That’s great.
    But here is a little problem with topical erectile dysfunction drug
    Actually more than one problem!

    First, the cream has to be applied each time a man wants to have sex
    Besides, what if a man’s erectile dysfunction is due to some organic malfunction?

    For instance, erectile dysfunction may be a warning sign of an impending heart attack
    Another risk for ED is lack of sleep.
    No topical spray or gel can fix that

    Without addressing the underlying cause[s] of ED, any solution is temporary
    But a worse scenario is that the man may be lulled into a false sense of health while that underlying cause[s] gets worse
    Diabetes and thyroid problem-that can cause constant fatigue-come to mind in this regard!

Comments are closed.